The 91±¬ÁÏ has Master Clinical Trial/Study & Confidentiality Agreements with many companies and Contract Research Organizations (CRO).
| Master Clinical Trial Agreement – Companies | Expiration |
|---|---|
| Abbvie Inc. | July 12, 2028 |
| Abiomed | None |
| Actelion | None |
| Activbiotics | None |
| Alkermes, Inc. | September 23, 2026 |
| Amgen | None |
| Aragon | None |
| Astellas | Under neg. |
| AstraZeneca | None |
| Bayer Corporation | None |
| BeOne Medicines USA, Inc. | August 21, 2030 |
| Biogen Idec | None |
| Boehringer Ingelheim Pharma | April 19, 2028 |
| Bristol Myers Squibb | January 19, 2025 |
| Bristol Myers Squibb Medical Imaging | None |
| Clovis | None |
| Cochlear Americas | None |
| Edwards Lifesciences, LLC | None |
| Eli Lilly and Company | None |
| EMD Serono, Inc. | None |
| Fred Hutchinson Incoming Subcontract Form | None |
| General Electric Co. (Comp. Research) | None |
| Genzyme Corporation | None |
| Hamilton Health Sciences (Coordinating Agreement) |
None |
| Hoffman-LaRoche, Inc. | None |
| Hoosier Oncology | None |
| Intermune | None |
| Jaeb Center for Health Research DRC | December 31, 2024 |
| Janssen Research & Development, LLC | December 7, 2026 |
| Medtronic, Inc. | May 12, 2026 |
| Merck | None |
| Millennium Pharmaceuticals | None |
| Novartis Pharmaceuticals Corp. | April 20, 2029 |
| Pfizer | March 1, 2024 |
| Pharmacyclics, Inc. | None |
| Renal Cancer Clinical Trial Consortium | None |
| Roche Laboratories | None |
| Sanofi-Aventis | March 6, 2025 |
| SC Liver Research Consortium | Ìý±·´Ç²Ô±ð |
| Seattle Genetics | January 31, 2025 |
| Vertex | None |
The following Master CTAs are through the Prostate Cancer Clinical Trial Consortium, and for members only.
| Prostate Cancer Clinical Trial Consortium – Master CTAs | Expiration |
|---|---|
| Aragon | None |
| Algeta ASA | None |
| BMS (PI-initiated trials only) | None |
| Hollis-Eden | None |
| ImaginAb, Inc. | None |
| Kinex Pharmaceuticals | None |
| Medivation | None |
| Sanofi | None |
| Master CDAs – Companies | Expiration |
|---|---|
| AbbVie | |
| Alkermes | None |
| Alpine | |
| Amgen Inc. | June 23, 2027 |
| AstraZeneca | None |
| Astellas Pharma Global | October 24, 2030 |
| Avenzo Therapeutics, Inc. | March 7, 2030 |
| Boehringer (2025) | June 13, 2030 |
| Bristol-Myers Squibb (2024) | February 1, 2029 |
| Catalyst Clinical Research | November 1, 2028 |
| Eli Lilly | Mutually Approved Template |
| GlaxoSmithKline | January 24, 2029 |
| Intel Corporation | No Expiration |
| Jaeb Center for Health Research (JCHR) | February 16, 2027 |
| Merck | |
| Novartis Pharmaceuticals Corporation | July 10, 2029 |
| Novotech | September 25, 2028 |
| Revolution Medicines | April 3, 2029 |
| Sanofi | None |
| Sumitomo Pharma Oncology, Inc. | December 20, 2033 |
| Vertex | June 29, 2026 |